Transparency Market Research discusses the nitty-gritties of the global panic attack treatment market through its new research report. The research report, titled “Panic Attack Treatment Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 – 2023,” evaluates the key elements of the global panic attack treatment market. Additionally, the research report also analyzes the market through SWOT analysis and Porter’s five forces analysis to highlight the impact of the prevailing competition on the trajectory of the market. The market has also been studied through political, economic, social, technological, legal, and environmental perspectives to give a complete picture of the global panic attack treatment market.
The global panic attack treatment market is segmented on the basis of drug class and geography. On the basis of drug class, the global panic attack treatment market is segmented into serotonin norepinephrine reuptake inhibitors (SNRI), benzodiazepines (BZD), and selective serotonin reuptake inhibitors (SSRI). The serotonin norepinephrine reuptake inhibitors segment further includes venlafaxine hydrochloride (Effexor XR). Meanwhile, the benzodiazepines segment is further divided into lorazepam, alprazolam (Niravam, Xanax), diazepam (Valium), and chlordiazepoxide (Librium). Lastly, the selectiveserotonin reuptake inhibitor class of drugs is further sub-segmented into paroxetine (Paxil, Pexeva), fluoxetine (Prozac), and sertraline (Zoloft). On the basis of geography, the global panic attack treatment market is segmented into Latin America, Asia Pacific, Europe, and North America.
Of all the types of drugs, the primary line of treatment for panic attacks is usually initiated with SSRI and SNRI. Most therapists steer away from benzodiazepines, as these are habit-forming drugs. Therefore, SSRI and SNRI hold a dominating presence in the global panic attack treatment market. Geographically, North America leads the global panic attack market due to the high incidence of panic attacks and better awareness amongst the overall population pertaining to anxiety-related disorders. Analysts predict that the Asia Pacific market for panic attack treatment will grow at a rapid pace in the coming years due to drastically changing lifestyles that are defined by high stress levels.
Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=7697
Some of the key players in the global panic attack treatment market are Recordati Rare Diseases, Sumitomo Dainippon Pharma, Eli Lilly and Company, Abbott Laboratories, Baxter International, Bristol-Myers Squibb, Actavis Pharmaceutical Company, F. Hoffmann-La Roche, Noven Pharmaceuticals, Inc., GlaxoSmithKlinePharmaceuticals Limited, Pfizer,Inc., and Shionogi and Company. The research report profiles these companies to offer a clear understanding of the competitive landscape of the global panic attack treatment market. Additionally, the report also gives an analysis of the financial overview, business and marketing strategies, research and development activities, investment outlook, product portfolio, and strategic mergers and acquisitions of these companies.
Transparency Market Research
90 State Street,
NY – 12207
USA – Canada Toll Free 866-552-3453